BPI-9016M
- Moderate, low or no solubility
- MF: C25H18F2N4O3
- MW: 460.43
Description
BPI-9016M is a potent, orally active, and selective tyrosine kinase inhibitor targeting both c-MET and AXL. It significantly suppressed tumor cell growth in lung adenocarcinoma PDX models, particularly in the tumors with high expression of c-Met.
More Information
| Parent CAS No. | 1528546-94-2 |
|---|---|
| Chemical Name | N-(4-(2,3-Dihydro-1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorophenyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide |
| extra_info | Sold in collaboration with Chemietek |
| MFCD | N.A. |
| Short Description | c-Met and AXL inhibitor |
References
- X Hu et al. First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
- P Zhang et al. BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1. Theranostics. 2018 Nov 12;8(21):5890-5902.
- C Jiang et al. Radiosensitizing effect of c-Met kinase inhibitor BPI-9016M in esophageal squamous cell carcinoma cells in vitro and in vivo. Ann Transl Med. 2021 Dec;9(24):1799.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1581 | SU 11274 |
From $99.00 |
| 1582 | Foretinib |
From $99.00 |
| 1583 | PF 04217903 mesylate |
From $88.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1916 | AMG 208 |
From $104.50 |
| 1946 | R 428 dihydrochloride |
From $88.00 |
| 1959 | Golvatinib |
From $99.00 |
| 2368 | Amuvatinib |
From $132.00 |
| 2553 | LY 2801653 |
From $132.00 |
| 3423 | Capmatinib |
From $88.00 |
| 3864 | Volitinib dihydrochloride |
From Inquiry |
| 3946 | Altiratinib |
From Inquiry |
| 3975 | MGCD265 dihydrochloride |
From $143.00 |
| 3998 | MGCD516 |
From Inquiry |
| 4040 | BMS-777607 |
From Inquiry |
